Mayer Brown represented Baxter International Inc. on the financing of Baxalta Incorporated, the new public company spun off by Baxter on July 1, 2015 that holds the former biopharmaceuticals business of Baxter. The financing consisted of a Rule 144A/Regulation S offering of $5 billion of senior notes of Baxalta and the concurrent tender offer by Baxter for approximately $3 billion of its outstanding public debt. The transaction also involved establishing new domestic and international credit facilities for each of Baxter and Baxalta.
The Chicago-based Mayer Brown team was led by Corporate & Securities partner David Schuette and included Corporate & Securities associates Christine Shepard, James Lisak and Nicole Puza; Banking & Finance partner Rob Baptista and associate Jennifer Bruni; and Tax Transactions & Consulting partner James Barry.
You have no pages selected. Please select pages to email then resubmit.